

Flp-In[™] T-REx[™] Core Kit

Version C

102201

25-0366

Flp-In[™] T-REx[™] Core Kit

**For Generating Stable, Inducible Mammalian
Expression Cell Lines by Flp Recombinase-
Mediated Integration**

Catalog no. K6500-01



www.invitrogen.com
tech_service@invitrogen.com

Table of Contents

Table of Contents	iii
Important Information	v
Accessory Products	vi
Introduction.....	1
The Flp-In™ T-REx™ System	1
Methods.....	10
Propagation and Maintenance of Plasmids.....	10
Generating Flp-In™ T-REx™ Host Cell Lines.....	12
Generating Flp-In™ T-REx™ Expression Cell Lines	21
Appendix	27
Recipes	27
Zeocin™	29
Blasticidin	31
pFRT/lacZeo Vector	32
pcDNA6/TR©	34
pOG44 Vector	36
Technical Service	38
Purchaser Notification	40
Product Qualification	44
References.....	45

Important Information

Shipping/Storage

The Flp-In™ T-REx™ Core Kit is shipped at room temperature. Upon receipt, remove the vectors and primers and store at -20°C. Store the tetracycline at +4°C protected from exposure to light. For long-term storage (> 6 months), store the tetracycline at -20°C protected from exposure to light.

Kit Contents

The Flp-In™ T-REx™ Core Kit contains the following reagents. Store at -20°C.

Note: For more information about pcDNA/FRT/TO® and pcDNA5/FRT/TO/CAT®, refer to the pcDNA5/FRT/TO® manual.

Reagent	Amount	Comments
pFRT/ <i>lacZeo</i>	20 g, lyophilized in TE, pH 8.0	Flp-In™ target site vector for creation of stable mammalian cell lines containing an integrated <u>F</u> lp <u>R</u> ecombination <u>T</u> arget (FRT) site
pcDNA6/TR®	20 g, lyophilized in TE, pH 8.0	Vector for constitutive expression of the Tet repressor
pOG44	20 g, lyophilized in TE, pH 8.0	Vector for transient expression of the Flp recombinase
pcDNA5/FRT/TO®	20 g, lyophilized in TE, pH 8.0	Inducible expression vector for cloning your gene of interest
pcDNA5/FRT/TO/CAT®	20 g, lyophilized in TE, pH 8.0	Positive control vector expressing the CAT gene
CMV Forward Primer (21-mer)	2 g (306 pmoles), lyophilized in TE, pH 8.0	5'-CGCAAATGGGCGGTAGGCGTG-3'
BGH Reverse Primer (18-mer)	2 g (358 pmoles), lyophilized in TE, pH 8.0	5'-TAGAAGGCACAGTCGAGG-3'
Tetracycline	5 g	Induction agent

Accessory Products

Introduction

The products listed in this section are intended for use with the Flp-In™ T-REx™ System. For more information, refer to our World Wide Web site (www.invitrogen.com) or call Technical Service (see page 38).

Additional Reagents

Many of the products included in the Flp-In™ T-REx™ Core Kit as well as other products that may be used in conjunction with the Flp-In™ T-REx™ System are available separately from Invitrogen. Ordering information is provided below.

Item	Amount	Catalog no.
pcDNA5/FRT/TO [®]	20 g, lyophilized	V6520-20
pFRT/ <i>lacZeo</i>	20 g, lyophilized	V6015-20
pFRT/ <i>lacZeo2</i>	20 g, lyophilized	V6022-20
pOG44	20 g, lyophilized	V6005-20
pcDNA6/TR [®]	20 g, lyophilized	V1025-20
CMV Forward Primer	2 g, lyophilized	N622-02
BGH Reverse Primer	2 g, lyophilized	N575-02
Tetracycline	5 g	Q100-19
Calcium Phosphate Transfection Kit	75 reactions	K2780-01

Selection Agents

The selection agents required for use in the Flp-In™ T-REx™ System may be obtained from Invitrogen. Ordering information is provided below.

Reagent	Amount Supplied	Catalog no.
Zeocin™	1 g	R250-01
	5 g	R250-05
Blasticidin	50 mg	R210-01
Hygromycin B	1 g	R220-05

continued on next page

Accessory Products, continued

Other Flp-In™ T-REx™ Products

A number of other Flp-In™ T-REx™ products are available from Invitrogen to facilitate expression of your gene of interest in the Flp-In™ T-REx™ System. The pcDNA5/FRT/TO[®] TOPO[®] TA Expression Kit allows rapid and efficient TOPO[®] Cloning of *Taq*-amplified PCR products into the pcDNA5/FRT/TO[®]-TOPO[®] vector. The Flp-In™ T-REx™-293 Cell Line contains a single integrated FRT site and stably expresses the Tet repressor, and allows the user to proceed directly to generation of the Flp-In™ T-REx™ expression cell line. For more information about these products, visit our World Wide Web site (www.invitrogen.com) or call Technical Service (see page 38).

Item	Amount	Catalog no.
pcDNA5/FRT/TO [®] TOPO [®] TA Expression Kit	20 reactions	K6510-20
Flp-In™ T-REx™-293 Cell Line	3 x 10 ⁶ cells, frozen	R780-07

Echo™-Adapted Acceptor Vector Kits

The Echo™ Cloning System allows fast and simplified cloning into multiple expression systems. The pcDNA5/FRT/TO[®] vector has been Echo™-adapted for use as an acceptor vector in the Echo™ Cloning System. The table below lists the different options available for entry from the Echo™ Cloning System into the Flp-In™ T-REx™ System. For more information about the Echo™ Cloning System, visit our World Wide Web site (www.invitrogen.com) or call Technical Service (see page 38).

Item	Catalog no.
pcDNA5/FRT/TO-E [®] Echo™-Adapted Acceptor Vector Kit	ET470-01
pcDNA5/FRT/TO-E [®] Echo™-Adapted Complete System Kit with:	
<i>pUniD/V5-His TOPO[®] Cloning Kit</i>	ET470-40C
<i>pUni/V5-His TOPO TA Cloning[®] Kit</i>	ET470-10C
<i>pUniBlunt/V5-His TOPO[®] Cloning Kit</i>	ET470-20C
<i>pUni/V5-His A, B, and C</i>	ET470-30C

Flp-In™ Host Cell Lines

For your convenience, Invitrogen has available several mammalian Flp-In™ host cell lines that stably express the *lacZ-Zeocin™* fusion gene from pFRT/*lacZeo* or pFRT/*lacZeo2* (Flp-In™-CHO). Each cell line contains a single integrated FRT site as confirmed by Southern blot analysis. By transfecting the pcDNA6/TR plasmid into these cell lines, you can easily generate Flp-In™ T-REx™ host cell lines. For more information, see our World Wide Web site (www.invitrogen.com) or call Technical Service (see page 38).

Cell Line	Amount	Catalog no.
Flp-In™-293	3 x 10 ⁶ cells, frozen	R750-07
Flp-In™-CV-1	3 x 10 ⁶ cells, frozen	R752-07
Flp-In™-CHO	3 x 10 ⁶ cells, frozen	R758-07

Introduction

The Flp-In™ T-REx™ System

Overview

The Flp-In™ T-REx™ System allows the generation of stable mammalian cell lines exhibiting tetracycline-inducible expression of a gene of interest from a specific genomic location. To generate these cell lines, the Flp-In™ T-REx™ System involves the following major steps:

1. Independent integration of two plasmids into the genome of the mammalian cell line of choice to generate a Flp-In™ T-REx™ host cell line
 - a) A plasmid containing a Flp Recombination Target (FRT) site
 - b) A plasmid expressing the Tet repressor
2. Integration of an expression vector containing your gene of interest under the control of a tetracycline-inducible promoter into the genome via Flp recombinase-mediated DNA recombination at the FRT site (O'Gorman *et al.*, 1991)
3. Induction of the gene of interest by the addition of tetracycline

Major Components of the System

The major components of the Flp-In™ T-REx™ System include:

A Flp-In™ target site vector, pFRT/*lacZeo*, for generation of a Flp-In™ host cell line containing an integrated FRT site

A Tet repressor expression plasmid, pcDNA6/TR®, for expression of the Tet repressor under the control of the human CMV promoter

An expression plasmid containing a FRT site linked to the hygromycin resistance gene for Flp recombinase-mediated integration and selection of a stable cell line expressing your gene of interest under the control of a tetracycline-regulated CMV/TetO₂ promoter

A Flp recombinase expression plasmid, pOG44, for expression of the Flp recombinase under the control of the human CMV promoter

A control expression plasmid containing the chloramphenicol acetyl transferase (*CAT*) gene, which when cotransfected with pOG44 into your Flp-In™ T-REx™ host cell line, expresses CAT upon induction with tetracycline

Advantages of the Flp-In™ T-REx™ System

Use of the Flp-In™ T-REx™ System to generate stable expression cell lines provides a number of advantages as described below:

Once the Flp-In™ T-REx™ host cell line containing an integrated FRT site has been created, subsequent generation of Flp-In™ T-REx™ cell lines expressing the gene(s) of interest is rapid and efficient.

The Flp-In™ T-REx™ System allows the generation of isogenic, inducible stable cell lines.

The Flp-In™ T-REx™ System permits polyclonal selection of stable expression cell lines.

continued on next page

The Flp-In™ T-REx™ System, continued

Generating Flp-In™ T-REx™ Host Cell Lines


The Flp-In™ T-REx™ System streamlines the generation of stable, inducible mammalian expression cell lines by taking advantage of a *Saccharomyces cerevisiae*-derived DNA recombination system. This DNA recombination system uses a recombinase (Flp) and site-specific recombination (Craig, 1988; Sauer, 1994) to facilitate integration of the gene of interest into a specific site in the genome of mammalian cells.

To generate a Flp-In™ T-REx™ host cell line, you will sequentially transfect two plasmids into the mammalian cell line of choice:


1. **pFRT/*lacZeo* target site vector:** The pFRT/*lacZeo* vector contains a *lacZ-Zeocin*™ fusion gene whose expression is controlled by the SV40 early promoter (see the **Appendix**, pages 32-33 for more information). A FRT site has been inserted just downstream of the ATG initiation codon of the *lacZ-Zeocin*™ fusion gene. The FRT site (see page 5 for more information) serves as the binding and cleavage site for the Flp recombinase. After transfection with pFRT/*lacZeo*, cells are selected with Zeocin™. Zeocin™-resistant clones are screened to identify those containing a single integrated FRT site. The resulting Flp-In™ host cell line contains a single integrated FRT site and expresses the *lacZ-Zeocin*™ fusion gene (see the figure below).
2. **pcDNA6/TR®:** The pcDNA6/TR® plasmid constitutively expresses the Tet repressor under the control of the human CMV promoter (see the figure below).

Note: Integration of the pFRT/*lacZeo* and pcDNA6/TR® plasmids into the genome is random and occurs independently.

1. pFRT/*lacZeo* is stably transfected into the mammalian cells of interest to generate the Zeocin™-resistant Flp-In™ Host Cell Line



2. The pcDNA6/TR® vector is stably transfected into the Flp-In™ Host Cell Line to generate the Zeocin-resistant, blasticidin-resistant Flp-In™ T-REx™ Host Cell Line



Flp-In™ T-REx™ Host Cell Line

continued on next page

The Flp-In™ T-REx™ System, continued

Generating Inducible Expression Cell Lines

Once you have generated a Flp-In™ T-REx™ host cell line, you will integrate the pcDNA5/FRT/TO® expression vector containing your gene of interest into the cells via Flp recombinase-mediated DNA recombination at the FRT site (O'Gorman *et al.*, 1991). This step requires the following plasmids:

1. **pcDNA5/FRT/TO® expression vector:** The pcDNA5/FRT/TO® plasmid contains your gene of interest under the control of a tetracycline-regulated, hybrid human cytomegalovirus (CMV)/TetO₂ promoter. The vector also contains the hygromycin resistance gene with a FRT site embedded in the 5' coding region. The hygromycin resistance gene lacks a promoter and the ATG initiation codon.
2. **pOG44:** The pOG44 plasmid constitutively expresses the Flp recombinase (Broach *et al.*, 1982; Broach and Hicks, 1980; Buchholz *et al.*, 1996) under the control of the human CMV promoter.

The pOG44 plasmid and the pcDNA5/FRT/TO® vector containing your gene of interest are cotransfected into the Flp-In™ T-REx™ host cell line. Upon cotransfection, the Flp recombinase expressed from pOG44 mediates a homologous recombination event between the FRT sites (integrated into the genome and on pcDNA5/FRT/TO®) such that the pcDNA5/FRT/TO® construct is inserted into the genome at the integrated FRT site (see the figure on the next page). Insertion of pcDNA5/FRT/TO® into the genome at the FRT site brings the SV40 promoter and the ATG initiation codon (from pFRT/*lacZeo*) into proximity and frame with the hygromycin resistance gene, and inactivates the *lacZ-Zeocin*™ fusion gene (see the figure on the next page). Thus, stable Flp-In™ T-REx™ expression cell lines can be selected for the following phenotypes:

Blasticidin resistance

Hygromycin resistance

Zeocin™ sensitivity

Lack of β -galactosidase activity

Once the pcDNA5/FRT/TO® vector has been stably integrated into the genome at the FRT site, expression of the recombinant protein of interest can be induced by the addition of tetracycline. For more information about the mechanism of tetracycline-induced expression of the gene of interest, refer to pages 6-7.

continued on next page


The Flp-In™ T-REx™ System, continued

Diagram of the Flp-In™ T-REx™ System


The figure below illustrates the major features of the Flp-In™ T-REx™ System as described on the previous page.

1. The pcDNA5/FRT/TO® expression vector containing your gene of interest (GOI) is cotransfected with pOG44 into the Flp-In™ T-REx™ Host Cell Line.

pcDNA5/FRT/TO® + pOG44



2. The Flp recombinase expressed from pOG44 catalyzes a homologous recombination event between the FRT sites in the host cells and the pcDNA5/FRT/TO expression vector.



3. Integration of the expression construct confers hygromycin resistance and Zeocin™ sensitivity to the cells. Expression of the gene of interest is repressed by the Tet repressor (TetR).



Flp-In™ T-REx™ Expression Cell Line

4. Expression of the gene of interest is induced by the addition of tetracycline.

+ tetracycline



Flp-In™ T-REx™ Expression Cell Line

continued on next page

The Flp-In™ T-REx™ System, continued

Flp Recombinase-Mediated DNA Recombination

In the Flp-In™ T-REx™ System, integration of your pcDNA5/FRT/TO® expression construct into the genome occurs via Flp recombinase-mediated intermolecular DNA recombination. The hallmarks of Flp-mediated recombination are listed below.

Recombination occurs between specific FRT sites (see below) on the interacting DNA molecules

Recombination is conservative and requires no DNA synthesis; the FRT sites are preserved following recombination and there is minimal opportunity for introduction of mutations at the recombination site

Strand exchange requires only the small 34 bp minimal FRT site (see below)

For more information about the Flp recombinase and conservative site-specific recombination, refer to published reviews (Craig, 1988; Sauer, 1994).

Note: If your cell line contains multiple integrated FRT sites, Flp-mediated intramolecular recombination may also occur. Intramolecular recombination may result in:


Excision of the intervening DNA if the FRT sites are directly repeated (*i.e.* integration of multiple FRT sites on the same DNA strand)

DNA inversion if the sites are in opposing orientations

Deletion of genomic sequences

FRT Sites

As described above, Flp recombinase-mediated recombination occurs between specific FRT sites. The FRT site, originally isolated from *Saccharomyces cerevisiae*, serves as a binding site for Flp recombinase and has been well-characterized (Gronostajski and Sadowski, 1985; Jayaram, 1985; Sauer, 1994; Senecoff *et al.*, 1985). The minimal FRT site consists of a 34 bp sequence containing two 13 bp imperfect inverted repeats separated by an 8 bp spacer that includes an *Xba* I restriction site (see figure below). An additional 13 bp repeat is found in most FRT sites, but is not required for cleavage (Andrews *et al.*, 1985). While Flp recombinase binds to all three of the 13 bp repeats, strand cleavage actually occurs at the boundaries of the 8 bp spacer region (see figure below for cleavage sites (CS)) (Andrews *et al.*, 1985; Senecoff *et al.*, 1985).



CS = cleavage site

continued on next page

The Flp-In[™] T-REx[™] System, continued

Tetracycline Regulation in the Flp-In[™] T-REx[™] System

The Flp-In[™] T-REx[™] System uses regulatory elements from the *E. coli* Tn10-encoded tetracycline (Tet) resistance operon (Hillen and Berens, 1994; Hillen *et al.*, 1983) to allow tetracycline-regulated expression of your gene of interest from pcDNA5/FRT/TO[®]. The mechanism of tetracycline regulation in the system is based on the binding of tetracycline to the Tet repressor and derepression of the promoter controlling expression of the gene of interest (Yao *et al.*, 1998). In the system, expression of your gene of interest is repressed in the absence of tetracycline and induced in the presence of tetracycline (Yao *et al.*, 1998).

Expression of your gene of interest from the pcDNA5/FRT/TO[®] vector is controlled by the human cytomegalovirus (CMV) promoter into which 2 tandem copies of the *tet* operator 2 (TetO₂) sequence have been inserted. The TetO₂ sequences consist of 2 copies of the 19 nucleotide sequence:

5'-TCCCTATCAGTGATAGAGA-3'

separated by a 2 base pair spacer (Hillen and Berens, 1994; Hillen *et al.*, 1983). Each 19 nucleotide TetO₂ sequence serves as the binding site for 2 molecules of the Tet repressor.

Mechanism of Repression/ Derepression

In the absence of tetracycline, the Tet repressor (expressed from the pcDNA6/TR[®] plasmid) forms a homodimer that binds with extremely high affinity to each TetO₂ sequence in the promoter of the pcDNA5/FRT/TO[®] vector (Hillen and Berens, 1994). The 2 TetO₂ sites in the promoter of pcDNA5/FRT/TO[®] serve as binding sites for 4 molecules (or 2 homodimers) of the Tet repressor (see figure on the next page). The affinity of the Tet repressor for the *tet* operator is $K_B = 2 \times 10^{11} \text{ M}^{-1}$ (as measured under physiological conditions), where K_B is the binding constant (Hillen and Berens, 1994). Binding of the Tet repressor homodimers to the TetO₂ sequences represses transcription of your gene of interest. Upon addition, tetracycline binds with high affinity to each Tet repressor homodimer in a 1:1 stoichiometry and causes a conformational change in the repressor that renders it unable to bind to the Tet operator. The association constant, K_A , of tetracycline for the Tet repressor is $3 \times 10^9 \text{ M}^{-1}$ (Hillen and Berens, 1994). The Tet repressor:tetracycline complex then dissociates from the Tet operator and allows induction of transcription from the gene of interest (see figure on the next page).

For more information about the *TetR* gene, see the **Appendix**, page 34.

continued on next page

The Flp-In™ T-REx™ System, continued

Diagram of Tetracycline Regulation


The figure below illustrates the mechanism of tetracycline-regulated repression and derepression of the gene of interest in the Flp-In™ T-REx™ System.

1. Tet repressor (tetR) protein is expressed from pcDNA6/TR® in the Flp-In™ T-REx™ cells.

2. TetR homodimers bind to Tet operator 2 (TetO₂) sequences in the pcDNA5/FRT/TO® vector, repressing transcription of the gene of interest.

3. Upon addition, tetracycline (tet) binds to tetR homodimers.

4. Binding of tet to tetR homodimers causes a conformational change in tetR, release from the Tet operator sequences, and induction of transcription from the gene of interest.



continued on next page

The Flp-In™ T-REx™ System, continued

Experimental Outline

To create a stable Flp-In™ T-REx™ cell line expressing your gene of interest at a site-specific genomic locus, you will perform the steps listed below (refer to the next page for a diagram).

1. Transfect the Flp-In™ target site vector, pFRT/*lacZeo* into the mammalian cell line of choice and screen for integrants containing a single FRT site.
2. Transfect the Tet repressor expression plasmid, pcDNA6/TR®, into a single site integrant (from Step 1) to generate the Flp-In™ T-REx™ host cell line.
3. Clone your gene of interest into the pcDNA5/FRT/TO® expression vector.
4. Co-transfect your pcDNA5/FRT/TO® construct and the Flp recombinase expression vector, pOG44, into your Flp-In™ T-REx™ host cell line to generate your Flp-In™ T-REx™ expression cell line.
5. Induce expression of the gene of interest with tetracycline.
6. Assay for expression of your recombinant protein of interest.


Note: The positive control vector containing the *CAT* gene can be cotransfected into your Flp-In™ T-REx™ host cell line with pOG44 to demonstrate that the system is working properly.

continued on next page

The Flp-In™ T-REx™ System, continued

Diagram of the Experimental Outline

The figure below illustrates the major steps necessary to generate a Flp-In™ T-REx™ expression cell line.



Methods

Propagation and Maintenance of Plasmids

Introduction

The following section contains guidelines for maintaining and propagating the pFRT/*lacZeo*, pcDNA6/TR[®], and pOG44 vectors. For information about maintaining and propagating the pcDNA5/FRT/TO[®] expression vector, refer to the vector manual.

General Molecular Biology Techniques

For assistance with *E. coli* transformations, restriction enzyme analysis, DNA biochemistry, and plasmid preparation, refer to *Molecular Cloning: A Laboratory Manual* (Sambrook *et al.*, 1989) or *Current Protocols in Molecular Biology* (Ausubel *et al.*, 1994).

E. coli Strain

Many *E. coli* strains are suitable for the propagation of the pFRT/*lacZeo*, pcDNA6/TR[®], and pOG44 vectors. We recommend that you propagate the vectors in *E. coli* strains that are recombination deficient (*recA*) and endonuclease A deficient (*endA*).

For your convenience, TOP10 and DH5 α [™]-T1^R *E. coli* are available as chemically competent or electrocompetent (TOP10 only) cells from Invitrogen.

Item	Quantity	Catalog no.
One Shot [®] TOP10 (chemically competent cells)	21 x 50 μ l	C4040-03
One Shot [®] TOP10 Electrocomp [™] (electrocompetent cells)	21 x 50 1	C4040-52
One Shot [®] DH5 α [™] -T1 ^R Max Efficiency [®] Chemically Competent Cells	21 x 50 1	12297-016

Transformation Method

You may use any method of choice for transformation. Chemical transformation is the most convenient for many researchers. Electroporation is the most efficient and the method of choice for large plasmids.

Maintenance of Plasmids

The pFRT/*lacZeo*, pcDNA6/TR[®], and pOG44 vectors contain the ampicillin gene to allow selection of the plasmid using ampicillin. **Note:** The pcDNA6/TR[®] plasmid also contains the blasticidin resistance gene to allow selection using blasticidin (see the next page).

To propagate and maintain the pFRT/*lacZeo*, pcDNA6/TR[®], and pOG44 plasmids, we recommend using the following procedure:

1. Resuspend each vector in 20 1 sterile water to prepare a 1 g/ 1 stock solution. Store the stock solution at -20°C.
 2. Use the stock solution to transform a *recA*, *endA* *E. coli* strain like TOP10, DH5 α [™]-T1^R, JM109, or equivalent.
 3. Select transformants on LB agar plates containing 50 to 100 g/ml ampicillin. For fast and easy microwaveable preparation of Low Salt LB agar containing ampicillin, imMedia[™] Amp Agar (Catalog no. Q601-20) is available from Invitrogen. For more information, call Technical Service (see page 38).
 4. Prepare a glycerol stock from each transformant containing plasmid for long-term storage (see the next page).
-

continued on next page

Propagation and Maintenance of Plasmids, continued

Selection of pcDNA6/TR[®] in *E. coli* Using Blasticidin

To propagate and maintain the pcDNA6/TR[®] plasmid in *E. coli* using blasticidin selection, follow Steps 1 and 2 of the protocol on the previous page. Select transformants on Low Salt LB agar plates containing 100 g/ml blasticidin.

Note: To facilitate selection of blasticidin-resistant *E. coli*, the salt concentration of the LB medium must remain low (< 90 mM) and the pH must be 7.0. **Failure to lower the salt content of your LB medium will result in non-selection due to inhibition of the drug unless a higher concentration of blasticidin is used.** A recipe to prepare Low Salt LB is provided in the **Appendix**, page 27.

Preparing a Glycerol Stock

Once you have identified the correct clone, be sure to purify the colony and make a glycerol stock for long-term storage. It is also a good idea to keep a DNA stock of your plasmid at -20°C.

1. Streak the original colony out on an LB plate containing 50 g/ml ampicillin. Incubate the plate at 37°C overnight.
 2. Isolate a single colony and inoculate into 1-2 ml of LB containing 50 g/ml ampicillin.
 3. Grow the culture to mid-log phase ($OD_{600} = 0.5-0.7$).
 4. Mix 0.85 ml of culture with 0.15 ml of sterile glycerol and transfer to a cryovial.
 5. Store at -80°C.
-

Generating Flp-In[™] T-REx[™] Host Cell Lines

Introduction

Before you can create a stable Flp-In[™] T-REx[™] cell line(s) which inducibly expresses your gene of interest, you will first need to generate a stable Flp-In[™] T-REx[™] host cell line. You will generate the Flp-In[™] T-REx[™] host cell line by independently transfecting the pFRT/*lacZeo* and pcDNA6/TR[®] plasmids into your mammalian cell line of interest. Once generated, the Flp-In[™] T-REx[™] host cell line will exhibit the following features:

Contains a single integrated FRT site (introduced by transfection of the pFRT/*lacZeo* plasmid)

Stably expresses the Tet repressor (introduced by transfection of the pcDNA6/TR[®] plasmid)

Guidelines to generate a Flp-In[™] T-REx[™] host cell line are provided in this section.

Experimental Outline

The table below outlines the steps necessary to generate a Flp-In[™] T-REx[™] host cell line. While it is possible to cotransfect pFRT/*lacZeo* and pcDNA6/TR[®], we recommend that you first generate a stable cell line containing a single integrated FRT site (from pFRT/*lacZeo*), and then use this cell line as the host for the pcDNA6/TR[®] plasmid.

Step	Action	Page
1	Transfect the pFRT/ <i>lacZeo</i> target site vector into the mammalian cell line of choice and select for Zeocin [™] -resistant transfectants.	13-17
2	Pick 20 Zeocin [™] -resistant foci and expand each clone.	17
3	Isolate genomic DNA and use Southern blot analysis to test for the number of integrated FRT sites.	17-18
4	Select the single integrants and screen for β -galactosidase activity.	18
5	Select the clone which exhibits the highest β -galactosidase activity and use this clone as the host for the pcDNA6/TR plasmid.	18
6	Transfect the pcDNA6/TR [®] plasmid into the host cell line containing the single integrated FRT site (see Step 5). Select for blasticidin-resistant transfectants.	19-20
7	Pick 20 blasticidin-resistant foci and screen for the clone which expresses the highest level of Tet repressor.	20



Note

Reminder: Once you have generated your Flp-In[™] T-REx[™] host cell line, the cells should exhibit the following phenotypes:

Zeocin[™] resistance

β -galactosidase activity

Blasticidin resistance

Expression of the Tet repressor

continued on next page

Generating Flp-In[™] T-REx[™] Host Cell Lines, continued



The Flp-In[™] T-REx[™]-293 host cell line which contains a single integrated FRT site and stably expresses the Tet repressor is available from Invitrogen (see page vii for ordering information). If you wish to inducibly express your gene of interest in 293 cells, you may want to use this cell line as the host and proceed directly to generate your stable expression cell line.

Alternatively, several Flp-In[™] host cell lines which contain a single integrated FRT site are also available from Invitrogen (see page vii for ordering information). You may transfect the pcDNA6/TR[®] plasmid into these cell lines to generate Flp-In[™] T-REx[™] host cell lines.

For more information about the Flp-In[™] T-REx[™]-293 cell line or the Flp-In[™] cell lines, refer to our Web site (www.invitrogen.com) or call Technical Service (see page 38).



Important

We have observed down-regulation of the viral CMV promoter and subsequent loss of gene expression when pcDNA5/FRT-based expression constructs are introduced into Flp-In[™]-3T3 or Flp-In[™]-BHK cells. We recommend that you **DO NOT** use 3T3 or BHK cells to generate your Flp-In[™] T-REx[™] host cell line.

Plasmid Preparation

Plasmid DNA for transfection into eukaryotic cells must be very clean and free from phenol and sodium chloride. Contaminants will kill the cells, and salt will interfere with lipids complexing, decreasing transfection efficiency. We recommend isolating DNA using the S.N.A.P.[™] MiniPrep Kit (10-15 g DNA, Catalog no. K1900-01), the S.N.A.P.[™] MidiPrep Kit (10-200 g DNA, Catalog no. K1910-01) or CsCl gradient centrifugation.

Methods of Transfection

For established cell lines (*e.g.* HeLa, COS-1), consult original references or the supplier of your cell line for the optimal method of transfection. We recommend that you follow exactly the protocol for your cell line. Pay particular attention to medium requirements, when to pass the cells, and at what dilution to split the cells. Further information is provided in *Current Protocols in Molecular Biology* (Ausubel *et al.*, 1994).

Methods for transfection include calcium phosphate (Chen and Okayama, 1987; Wigler *et al.*, 1977), lipid-mediated (Felgner *et al.*, 1989; Felgner and Ringold, 1989) and electroporation (Chu *et al.*, 1987; Shigekawa and Dower, 1988). Invitrogen offers the Calcium Phosphate Transfection Kit (Catalog no. K2780-01) and several lipid-based reagents for mammalian cell transfection. For more information on the reagents available, see our Web site (www.invitrogen.com) or call Technical Service (see page 38).

Zeocin[™]

The pFRT/*lacZeo* plasmid contains a *lacZ-Zeocin[™]* fusion gene under the control of the SV40 early promoter. Expression of the *lacZ-Zeocin[™]* fusion gene allows selection of stable integrants using Zeocin[™] antibiotic. The resulting stable integrants can then be screened by assaying for expression of β -galactosidase. For more information about preparing and handling Zeocin[™], refer to the **Appendix**, pages 29-30.

continued on next page

Generating Flp-In[™] T-REX[™] Host Cell Lines, continued

Determination of Zeocin[™] Sensitivity

To successfully generate a stable cell line containing an integrated FRT site and expressing the β -galactosidase-Zeocin[™] fusion protein, you need to determine the minimum concentration of Zeocin[™] required to kill your untransfected mammalian cell line. Typically, concentrations ranging from 50 to 1000 g/ml Zeocin[™] are sufficient to kill most untransfected mammalian cell lines, with the average being 100 to 400 g/ml. We recommend that you test a range of concentrations (see protocol below) to ensure that you determine the minimum concentration necessary for your cell line. Refer to the **Appendix**, pages 29-30 for instructions on how to prepare and store Zeocin[™].

1. Plate or split a confluent plate so the cells will be approximately 25% confluent. Prepare a set of 7 plates. Allow cells to adhere overnight.
2. The next day, substitute culture medium with medium containing varying concentrations of Zeocin[™] (0, 50, 100, 250, 500, 750, and 1000 g/ml Zeocin[™]).
3. Replenish the selective media every 3-4 days, and observe the percentage of surviving cells.
4. Note the percentage of surviving cells at regular intervals to determine the appropriate concentration of Zeocin[™] that kills the cells within 1-2 weeks after addition of Zeocin[™].

Effect of Zeocin[™] on Sensitive and Resistant Cells

Zeocin[™]'s method of killing is quite different from other antibiotics including hygromycin, G418, and blasticidin. **Cells do not round up and detach from the plate.** Sensitive cells may exhibit the following morphological changes upon exposure to Zeocin[™]:

Vast increase in size (similar to the effects of cytomegalovirus infecting permissive cells)

Abnormal cell shape

Presence of large empty vesicles in the cytoplasm (breakdown of the endoplasmic reticulum and Golgi apparatus, or other scaffolding proteins)

Breakdown of plasma and nuclear membrane (appearance of many holes in these membranes)

Eventually, these "cells" will completely break down and only "strings" of protein remain.

Zeocin[™]-resistant cells should continue to divide at regular intervals to form distinct colonies. There should not be any distinct morphological changes in Zeocin[™]-resistant cells when compared to cells not under selection with Zeocin[™]. For more information about Zeocin[™] and its mechanism of action, refer to the **Appendix**, pages 29-30.

continued on next page

Generating Flp-In[™] T-REx[™] Host Cell Lines, continued

Transfection Considerations

Once you have determined the appropriate Zeocin[™] concentration to use for selection, you are ready to transfect the pFRT/*lacZeo* plasmid into your mammalian cell line of choice. Before beginning, you will need to consider the following factors:

Insertion of the FRT site into the genome: Integration of the pFRT/*lacZeo* plasmid containing the FRT site into the genome will occur randomly. Subsequent integration of the pcDNA5/FRT/TO[®] expression plasmid containing your gene of interest will occur through Flp recombinase-mediated recombination at the genomic FRT site.

Transfection efficiency of your cell line: The aim of most users will be to create stable cell lines containing a single integrated FRT site (“single integrants”; see **Note** below). The probability of obtaining stable integrants containing a single FRT site or multiple FRT sites will depend upon the transfection efficiency of your cell line and the amount of DNA transfected. To increase the likelihood of obtaining single integrants, you will need to lower the transfection efficiency by limiting the amount of plasmid DNA that you transfect (see **Recommendation** on the next page).

Selection of foci: You will select for stable transfectants by plating cells in medium containing Zeocin[™]. Zeocin[™]-resistant foci can then be screened by Southern blot analysis to identify single integrants. To increase the chances of obtaining single integrants, we recommend that you pick foci from plates that have been transfected with the least amount of plasmid DNA.

Chromosomal position effects: Because integration of the pFRT/*lacZeo* plasmid into the genome occurs randomly, expression levels of the *lacZ-Zeocin*[™] fusion gene will be dependent on the transcriptional activity of the surrounding sequences at the integration site (*i.e.* chromosomal position effect). Once you have obtained single integrants, you may want to screen the Zeocin[™]-resistant clones for those expressing the highest β -galactosidase levels. Those clones expressing the highest levels of β -galactosidase should contain single FRT sites which have integrated into the most transcriptionally active regions.

Antibiotic concentration: Single integrants will express only a single copy of the *lacZ-Zeocin*[™] fusion gene and therefore, may be more sensitive to Zeocin[™] selection than multiple integrants. If you have previously used your mammalian cell line for transfection and Zeocin[™] selection, note that you may need to use lower concentrations of Zeocin[™] to obtain single integrants.



Note

Because transfection efficiency is dependent upon the nature of your cell line and the amount of DNA transfected, it is possible to generate a cell line containing multiple integrated FRT sites. In theory, cotransfection of your pcDNA5/FRT/TO[®] construct and pOG44 into these cells will allow integration of your gene of interest into multiple genomic loci. We do not recommend generating a Flp-In[™] T-REx[™] host cell line which contains multiple integrated FRT sites for the following reasons:

Because expression of your gene of interest is based upon a repression/derepression mechanism, the amount of Tet repressor produced in your Flp-In[™] T-REx[™] host cell line may not be sufficient to repress basal transcription of your gene if the expression plasmid can integrate into multiple genomic loci.

Proper tetracycline regulated expression of your gene of interest may be more difficult to achieve.

The presence of multiple integrated FRT sites in the genome may increase the occurrence of chromosomal rearrangements or unexpected recombination events in your host cell line.

continued on next page

Generating Flp-InTM T-RExTM Host Cell Lines, continued



As mentioned previously on page 15, we recommend that you transfect your mammalian cell line with a limiting amount of pFRT/*lacZeo* plasmid. We generally use 250 ng to 2 μ g of plasmid DNA per 4×10^6 cells for transfection, but the amount of plasmid DNA may vary due to the nature of the cell line, the transfection efficiency of your cells, and the method of transfection used. When transfecting your mammalian cell line of choice, we suggest that you try a range of plasmid DNA concentrations (e.g. 0.25, 0.5, 1, 2, 5 μ g/ml DNA) to optimize transfection conditions for your cell line.

We generally use electroporation to transfect cells, but other methods of transfection are suitable. For a protocol to electroporate cells, refer to *Current Protocols in Molecular Biology*, Unit 9.3 (Ausubel *et al.*, 1994). Note that if you use calcium phosphate or lipid-mediated transfection methods, the amount of **total** DNA required for transfection is typically higher than for electroporation (usually between 10 and 20 μ g DNA). Depending on the amount of pFRT/*lacZeo* plasmid that you use for transfection, you may need to supplement your plasmid DNA with carrier DNA (e.g. salmon sperm DNA).

Possible Sites for Linearization of pFRT/*lacZeo*

To obtain stable transfectants, we recommend that you linearize the pFRT/*lacZeo* plasmid before transfection. While linearizing the vector may not improve the efficiency of transfection, it increases the chances that the vector does not integrate in a way that disrupts the ATG-FRT-*lacZ*-ZeocinTM cassette or other elements necessary for expression in mammalian cells. The table below lists unique sites that may be used to linearize your construct prior to transfection. Other restriction sites are possible.

Note: We generally use *Sca*I to linearize pFRT/*lacZeo*.

Enzyme	Restriction Site (bp)	Location	Supplier
<i>Tth</i> 111 I	125	Backbone	Many
<i>Apa</i> I	5617	Backbone	Invitrogen (Catalog no. 15440-019)
<i>Swa</i> I	6075	Backbone	New England Biolabs, Sigma, Takara
<i>Xmn</i> I	6487	Ampicillin gene	Many
<i>Sca</i> I I	6606	Ampicillin gene	Invitrogen (Catalog no. 15436-017)
<i>Bsa</i> I	7021	Ampicillin gene	New England Biolabs
<i>Eam</i> 1105 I	7087	Ampicillin gene	AGS*, Fermentas, Takara
<i>Sap</i> I	8092	Backbone	New England Biolabs

*Angewandte Gentechnologie Systeme

continued on next page

Generating Flp-In[™] T-REX[™] Host Cell Lines, continued

Selection of Stable pFRT//lacZeo Integrants

Once you have determined the appropriate Zeocin[™] concentration to use for selection, you can generate a stable cell line with pFRT//lacZeo.

1. Transfect mammalian cells with the appropriate amount of pFRT//lacZeo (see previous page) using the desired protocol. Remember to include a plate of untransfected cells as a negative control.
2. 24 hours after transfection, wash the cells and add fresh medium to the cells.
3. 48 hours after transfection, split the cells into fresh medium. Split the cells such that they are no more than 25% confluent. If the cells are too dense, the antibiotic will not kill the cells. Antibiotics work best on actively dividing cells.
4. Incubate the cells at 37°C for 2-3 hours until they have attached to the culture dish.
5. Remove the medium and add fresh medium containing Zeocin[™] at the pre-determined concentration required for your cell line.
6. Feed the cells with selective medium every 3-4 days until foci can be identified.
7. Pick at least 20 Zeocin[™]-resistant foci and expand each clone to test for the number of integrated FRT sites. Isolate genomic DNA and use Southern blot analysis to distinguish between single and multiple integrants (see below and the next page). Select the single integrants and proceed to the next step.
8. Screen the single integrants for β -galactosidase activity (see the next page). Select those clones which exhibit the highest levels of β -galactosidase expression to use as your host for the pcDNA6/TR[®] plasmid.
9. Once you have obtained a stable Flp-In[™] cell line, you can use this cell line to isolate a stable cell line expressing the Tet repressor from the pcDNA6/TR[®] plasmid (see pages 19-20). **Note:** Remember to maintain the Flp-In[™] host cell line in medium containing the appropriate amount of Zeocin[™].

Isolation of Genomic DNA

Once you have obtained Zeocin[™]-resistant foci, you will need to expand the cells and isolate genomic DNA. You may use any standard protocol to isolate genomic DNA from your cells. Protocols may be found in *Current Protocols in Molecular Biology* (Ausubel *et al.*, 1994) or *Molecular Cloning: A Laboratory Manual* (Sambrook *et al.*, 1989). For easy isolation of genomic DNA, the Easy-DNA[™] Kit (Catalog no. K1800-01) is available from Invitrogen. Call Technical Service for more information (see page 38).

continued on next page

Generating Flp-In[™] T-REx[™] Host Cell Lines, continued

Screening Clones by Southern Blot Analysis

You can use Southern blot analysis to determine the number of integrated FRT sites present in each of your Zeocin[™]-resistant clones. When performing Southern blot analysis, you should consider the following factors:

Probe: We recommend that you use a fragment of the *lacZ* gene (100 to 500 bp) as the probe to screen your samples. Mammalian cells do not contain an endogenous *lacZ* gene, therefore, a *lacZ* probe should allow you to identify those clones which contain pFRT/*lacZeo* DNA. To label the probe, we generally use a standard random priming kit (e.g. Ambion, DECAprime II[™] Kit, Catalog no. 1455). Other random priming kits are suitable.

Restriction digest: When choosing a restriction enzyme to digest the genomic DNA, we recommend choosing an enzyme that cuts at a single known site outside of the *lacZ* gene in the pFRT/*lacZeo* vector. Hybridization of the *lacZ* probe to digested DNA should then allow you to detect a single band containing the *lacZ* gene from pFRT/*lacZeo*. We generally use *Hind* III to digest genomic DNA from the Zeocin[™]-resistant clones. pFRT/*lacZeo* contains a single *Hind* III site within the FRT site.

Protocol: You may use any Southern blotting protocol of your choice. Refer to *Current Protocols in Molecular Biology* (Ausubel *et al.*, 1994) or *Molecular Cloning: A Laboratory Manual* (Sambrook *et al.*, 1989) for detailed protocols.

What You Should See

If you digest genomic DNA from your transfectants with *Hind* III and use a *lacZ* fragment as a probe in your Southern analysis, you should be able to easily distinguish between single and multiple FRT integrants.

DNA from single integrants should contain only one hybridizing band corresponding to a single copy of the integrated pFRT/*lacZeo* plasmid.

DNA from multiple integrants should contain more than one hybridizing band. If the pFRT/*lacZeo* plasmid integrates into multiple chromosomal locations, the bands may be of varying sizes.

Assay for β -Galactosidase Activity

Once you have identified single integrants, proceed to screen the clones for β -galactosidase expression. You may assay for β -galactosidase expression by activity assay using cell-free lysates (Miller, 1972) or by staining the cells for activity. Invitrogen offers the β -Gal Assay Kit (Catalog no. K1455-01) and the β -Gal Staining Kit (Catalog no. K1465-01) for fast and easy detection of β -galactosidase expression. Select those clones expressing the highest levels of β -galactosidase (if desired) to use as the host cell lines for the pcDNA6/TR[©] plasmid.

continued on next page

Generating Flp-In™ T-REx™ Host Cell Lines, continued

Determination of Blasticidin Sensitivity

Once you have generated a Flp-In™ cell line containing a single integrated FRT site, you will transfect the pcDNA6/TR[®] plasmid into these cells to generate a Flp-In™ T-REx™ host cell line. The pcDNA6/TR[®] plasmid contains the blasticidin resistance gene (*bsd*) to allow selection of stable transfectants. Before proceeding, we recommend that you determine the minimum concentration of blasticidin required to kill your untransfected Flp-In™ host cell line. Use the protocol on page 14 with the following exceptions:

Typically, concentrations ranging from 2.5 to 10 µg/ml blasticidin are sufficient to kill most untransfected mammalian cell lines.

Selection should be complete within 10 days after addition of the antibiotic.

Refer to the **Appendix**, page 31 for instructions on how to prepare and store blasticidin.

Possible Sites for Linearization of pcDNA6/TR[®]

As with transfection of pFRT/*lacZeo*, we also recommend that you linearize the pcDNA6/TR[®] plasmid before transfection. The table below lists unique sites that may be used to linearize your construct prior to transfection. Other restriction sites are possible.

Enzyme	Restriction Site (bp)	Location	Supplier
<i>Bst</i> 1107 I	4470	Backbone	AGS*, Fermentas, Takara
<i>Sap</i> I	4733	Backbone	New England Biolabs
<i>Bsp</i> LU11 I	4849	Backbone	Boehringer-Mannheim
<i>Eam</i> 1105 I	5739	Ampicillin gene	AGS*, Fermentas, Takara
<i>Fsp</i> I	5961	Ampicillin gene	Many

*Angewandte Gentechnologie Systeme

continued on next page

Generating Flp-In™ T-REx™ Host Cell Lines, continued

Selection of Stable pcDNA6/TR® Integrants

Once you have determined the appropriate blasticidin concentration to use for selection, you can generate a stable cell line expressing the Tet repressor from pcDNA6/TR®. **Reminder:** Since you are using transfecting pcDNA6/TR® into the Flp-In™ host cell line, remember to maintain cells in medium containing Zeocin™.

1. Transfect your Flp-In™ host cell line with the pcDNA6/TR® plasmid using the desired protocol. Remember to include a plate of untransfected cells as a negative control.
 2. 24 hours after transfection, wash the cells and add fresh medium to the cells.
 3. 48 hours after transfection, split the cells into fresh medium. Split the cells such that they are no more than 25% confluent.
 4. Incubate the cells at 37°C for 2-3 hours until they have attached to the culture dish.
 5. Remove the medium and add fresh medium containing blasticidin at the pre-determined concentration required for your cell line.
 6. Feed the cells with selective medium every 3-4 days until foci can be identified.
 7. Pick at least 20 blasticidin-resistant foci and expand them to test for tetracycline-inducible gene expression by transiently transfecting with the pcDNA5/FRT/TO/CAT® positive control plasmid expressing CAT. Screen for those clones which exhibit the lowest levels of basal transcription and the highest levels of CAT expression after addition of tetracycline (see below). For guidelines to prepare and use tetracycline, see pages 24 and 26.
 8. Once you have obtained a stable Flp-In™ T-REx™ cell line, you can use this cell line to isolate a stable cell line expressing your gene of interest from the pcDNA5/FRT/TO® plasmid. **Note:** Remember to maintain the Flp-In™ T-REx™ host cell line in medium containing the appropriate amount of Zeocin™ and blasticidin.
-



Important

Because tetracycline-regulated expression in the Flp-In™ T-REx™ System is based on a repression/derepression mechanism, the amount of Tet repressor that is expressed in the Flp-In™ T-REx™ host cell line from pcDNA6/TR® will determine the level of transcriptional repression of the Tet operator sequences in your pcDNA5/FRT/TO® expression construct. Tet repressor levels should be sufficiently high to suitably repress basal level transcription. Therefore, when screening your blasticidin-resistant clones, we recommend selecting those clones which exhibit the lowest basal levels of CAT expression (see above) to use as the host(s) for your pcDNA5/FRT/TO® construct. These clones should be exhibiting the highest levels of Tet repressor expression.

Assay for CAT Protein

The CAT protein expressed from the pcDNA5/FRT/TO/CAT® control plasmid is approximately 32 kDa in size. You may assay for CAT expression by ELISA assay, Western blot analysis, fluorometric assay, or radioactive assay (Ausubel *et al.*, 1994; Neumann *et al.*, 1987). The Anti-CAT Antiserum (Catalog no. R902-25) is available from Invitrogen for detection of CAT protein by Western blot analysis. Other commercial kits to assay for CAT protein are also available from 5 Prime to 3 Prime, Inc. (Catalog no. 5307-899129) and Molecular Probes (Catalog no. F-2900).

Generating Flp-In™ T-REx™ Expression Cell Lines

Introduction

Once you have established your Flp-In™ T-REx™ host cell line, you may cotransfect your pcDNA5/FRT/TO[®] construct and the pOG44 expression plasmid into the host cell line to generate a stable Flp-In™ T-REx™ expression cell line which inducibly expresses your gene of interest. Integration of the pcDNA5/FRT/TO[®] construct into the genome will occur at the FRT site in the Flp-In™ T-REx™ host cells. The pcDNA5/FRT/TO[®] plasmid contains the hygromycin resistance gene to allow selection of stable cell lines (see below). For more information about the pcDNA5/FRT/TO[®] plasmid and cloning your gene of interest into pcDNA5/FRT/TO[®], refer to the vector manual. For more information about the pOG44 plasmid, see below.



Important

The hygromycin resistance gene in the pcDNA5/FRT/TO[®] vector lacks an ATG initiation codon and a promoter to drive expression of the gene. Transfection of pcDNA5/FRT/TO[®] plasmid alone into a Flp-In™ T-REx™ host cell line will **not** confer hygromycin resistance to the cells containing the plasmid. The ATG initiation codon and the SV40 promoter required for expression of the hygromycin resistance gene are brought into proximity and frame with the gene **only** through Flp recombinase-mediated recombination between the FRT sites in the pcDNA5/FRT/TO[®] plasmid and the Flp-In™ T-REx™ host cell line.



If you wish to express your gene of interest in 293 cells, you may want to use the Flp-In™ T-REx™-293 host cell line available from Invitrogen to establish your expression cell line (see page vii for ordering information). For more information, refer to our World Wide Web site (www.invitrogen.com) or call Technical Service (see page 38).



Note

It is also possible to cotransfect pcDNA5/FRT/TO[®] and pOG44 into a Flp-In™ host cell line to generate an expression cell line. Flp-In™ host cell lines contain a single integrated FRT site, but do not express the Tet repressor. Cotransfection of pcDNA5/FRT/TO[®] and pOG44 into a Flp-In™ host cell line would allow integration of the pcDNA5/FRT/TO[®] construct into the genome via the FRT sites. However, in this case, the TetO₂ sequences in the hybrid CMV/TetO₂ promoter of pcDNA5/FRT/TO[®] are inert and the CMV/TetO₂ promoter functions to allow constitutive expression of your gene of interest at levels similar to the native CMV promoter.

pOG44 Plasmid

You will cotransfect the pOG44 plasmid and your pcDNA5/FRT/TO[®] construct into your Flp-In™ T-REx™ host cell line to generate stable cell lines that inducibly express your protein of interest. Cotransfection of pOG44 and pcDNA5/FRT/TO[®] allows expression of Flp recombinase and integration of the pcDNA5/FRT/TO[®] plasmid into the genome via the FRT sites. Once the pcDNA5/FRT/TO[®] construct has integrated into the genome, the Flp recombinase is no longer required. The continued presence of Flp recombinase would actually be detrimental to the cells because it could mediate excision of your pcDNA5/FRT/TO[®] construct.

The pOG44 plasmid lacks an antibiotic resistance marker for selection in mammalian cells. Thus, the plasmid and therefore, Flp recombinase expression, will gradually be lost from transfected cells as they are cultured and selected in hygromycin.

continued on next page

Generating Flp-In[™] T-REx[™] Expression Cell Lines, continued

Flp Recombinase

The *FLP* gene was originally isolated from the *Saccharomyces cerevisiae* 2⁺ plasmid (Broach *et al.*, 1982; Broach and Hicks, 1980) (see the **Appendix**, page 36 for more information). When tested in mammalian cells, the Flp recombinase has been shown to possess optimum recombination activity near 30°C and relatively low activity at 37°C, a result consistent with its physiological role in yeast (Buchholz *et al.*, 1996).

The *FLP* gene in pOG44 is further limited in its activity because it contains a point mutation that encodes a Flp recombinase with a phenylalanine to leucine amino acid substitution at position 70 (Buchholz *et al.*, 1996). The resulting Flp recombinase (flp-F70L) exhibits increased thermolability at 37°C in mammalian cells when compared to the native Flp recombinase (Buchholz *et al.*, 1996). Studies have shown that the Flp recombinase expressed from pOG44 possesses only 10% of the activity at 37°C of the native Flp recombinase (Buchholz *et al.*, 1996).



Important

When generating Flp-In[™] T-REx[™] expression cell lines, it is important to remember that you are selecting for a relatively rare recombination event since you want recombination and integration of your pcDNA5/FRT/TO[®] construct to occur only through the FRT site and for a limited time. In this case, using a highly inefficient Flp recombinase is beneficial and may decrease the occurrence of other undesirable recombination events.



Note

Reminder: Integration of the pcDNA5/FRT/TO[®] construct into the genome via the FRT sites will result in the following events (see page 4 for a diagram):

- Insertion of the hygromycin resistance gene downstream of the SV40 early promoter and the ATG initiation codon (provided by pFRT/*lacZeo*)

- Insertion of the plasmid containing the CMV/TetO₂ promoter, your gene of interest, and the BGH polyadenylation signal upstream of the *lacZ-Zeocin*[™] fusion gene

- Disruption of the functional *lacZ-Zeocin*[™] transcriptional unit caused by loss of the SV40 early promoter and the ATG initiation codon and insertion of the cassette containing the CMV/TetO₂ promoter, gene of interest, and the BGH polyadenylation signal

As a result, your Flp-In[™] T-REx[™] expression cell lines should exhibit the following phenotype:

- Hygromycin resistance

- Zeocin[™] sensitivity

- Lack of β-galactosidase activity

- Blasticidin resistance

- Tetracycline-regulated expression of the gene of interest

continued on next page

Generating Flp-In™ T-REx™ Expression Cell Lines, continued

Positive Control

The pcDNA5/FRT/TO/CAT® plasmid is provided as a positive control vector for mammalian cell transfection and expression and may be used to assay for expression levels in your Flp-In™ T-REx™ expression cell line. If you have several different Flp-In™ T-REx™ host cell lines (cell lines containing FRT sites integrated at different genomic loci), you may want to use the pcDNA5/FRT/TO/CAT® control vector to compare protein expression levels from the various genomic loci.

For more information about pcDNA5/FRT/TO/CAT®, refer to the pcDNA5/FRT/TO® vector manual.

Hygromycin B

The pcDNA5/FRT/TO® vector contains the *E. coli* hygromycin resistance gene (*HPH*) (Gritz and Davies, 1983) for selection of transfectants with the antibiotic, hygromycin B (Palmer *et al.*, 1987). When added to cultured mammalian cells, hygromycin B acts as an aminocyclitol to inhibit protein synthesis by disrupting translocation and promoting mistranslation. Hygromycin B liquid is available separately from Invitrogen (see page vi for ordering information).



Hygromycin B is light sensitive. Store the liquid stock solution at +4°C protected from exposure to light.

Hygromycin B is toxic. Do not ingest solutions containing the drug.

Wear gloves, a laboratory coat, and safety glasses or goggles when handling hygromycin B and hygromycin B-containing solutions.

Preparing and Storing Hygromycin B

The hygromycin B available from Invitrogen is supplied as a 100 mg/ml stock solution in autoclaved, deionized water and is filter-sterilized. The solution is brown in color. The stability of hygromycin B is guaranteed for six months, if stored at +4°C. Medium containing hygromycin is stable for up to six weeks.

Determination of Hygromycin Sensitivity

To successfully generate a stable cell line expressing your gene of interest from pcDNA5/FRT/TO®, you need to determine the minimum concentration of hygromycin B required to kill your untransfected Flp-In™ T-REx™ host cell line. Typically, concentrations ranging from 10 to 400 µg/ml hygromycin B are sufficient to kill most untransfected mammalian cell lines. We recommend that you test a range of concentrations (0, 10, 50, 100, 200, 400, 600 µg/ml hygromycin B) to ensure that you determine the minimum concentration necessary for your Flp-In™ T-REx™ host cell line.

continued on next page

Generating Flp-In™ T-REx™ Expression Cell Lines, continued

Tetracycline

Tetracycline (MW = 444.4) is commonly used as a broad spectrum antibiotic and acts to inhibit translation by blocking polypeptide chain elongation in bacteria. In the Flp-In™ T-REx™ System, tetracycline is used as an inducing agent to induce transcription of the gene of interest from the pcDNA5/FRT/TO[®] expression vector. Tetracycline induces transcription by binding to the Tet repressor homodimer and causing the repressor to undergo a conformational change that renders it unable to bind to the Tet operator. The association constant of tetracycline to the Tet repressor is $3 \times 10^9 \text{ M}^{-1}$ (Takahashi *et al.*, 1991). Tetracycline is supplied with the Flp-In™ T-REx™ Core Kit, but may also be obtained separately from Invitrogen (see page vi for ordering information).

Note: The concentrations of tetracycline used to induce gene expression in the Flp-In™ T-REx™ System are generally not high enough to be toxic to mammalian cells.

Tetracycline-Reduced Serum

When culturing cells in medium containing fetal bovine serum (FBS), note that many lots of FBS contain tetracycline as FBS is generally isolated from cows that have been fed a diet containing tetracycline. If you culture your cells in medium containing FBS that is not reduced in tetracycline, you may observe low basal expression of your gene of interest in the absence of tetracycline. We have cultured our mammalian cells in medium containing FBS that may not be reduced in tetracycline, and have observed undetectable to very low basal expression of CAT from the positive control vector in the absence of additional tetracycline. If your gene of interest produces a toxic protein, you may wish to culture your cells in tetracycline-reduced FBS. For more information, consult the supplier of your serum.



Tetracycline is light sensitive. Store the powdered drug at +4°C in the dark. Prepare medium containing tetracycline immediately before use.

Tetracycline is toxic. Do not ingest or inhale the powder or solutions containing the drug.

Wear gloves, a laboratory coat, and safety glasses or goggles when handling tetracycline and tetracycline-containing solutions.

Preparation of Tetracycline

To prepare tetracycline:

1. Weigh out 10 mg of tetracycline (provided in the Flp-In™ T-REx™ Core Kit) and transfer to a sterile 15 ml conical polypropylene tube.
2. Resuspend 10 mg of tetracycline in 10 ml of 100% ethanol. This will provide you with 1 mg/ml stock solution of tetracycline that is yellow in color.
3. Store the stock solution at -20°C protected from exposure to light.

continued on next page

Generating Flp-In[™] T-REx[™] Expression Cell Lines, continued



Because correct integration of your pcDNA5/FRT/TO[®] construct into the genome is dependent on Flp recombinase, the expression levels of Flp recombinase in the cell will determine the efficiency of the recombination reaction. Flp recombinase levels must be sufficiently high to mediate recombination at the FRT sites (single recombination event) and overcome the low intrinsic activity of the enzyme (see page 22). We have varied the ratio of pOG44 and pcDNA5/FRT/TO[®] expression plasmid that we cotransfect into mammalian Flp-In[™] T-REx[™] host cells to optimize the recombination efficiency. **We recommend that you cotransfect your Flp-In[™] T-REx[™] host cell line with a ratio of at least 9:1 (w/w) pOG44:pcDNA5/FRT/TO[®] expression plasmid.** Note that this ratio may vary depending on the nature of the cell line. You may want to determine this ratio empirically for your cell line.



When transfecting your Flp-In[™] T-REx[™] host cell line, be sure to use supercoiled pOG44 and pcDNA5/FRT/TO[®] plasmid DNA. Flp-mediated recombination between the FRT site on pcDNA5/FRT/TO[®] and the integrated FRT site in the Flp-In[™] T-REx[™] host cell line will only occur if the pcDNA5/FRT/TO[®] plasmid is circularized. The pOG44 plasmid should be circularized to minimize the possibility of the plasmid integrating into the genome.

Selection of Stable Flp-In[™] T-REx[™] Expression Cell Lines

Once you have determined the appropriate hygromycin concentration to use for selection in your Flp-In[™] T-REx[™] host cell line, you can generate a stable cell line which inducibly expresses your pcDNA5/FRT/TO[®] construct. **Reminder: Following cotransfection, your Flp-In[™] T-REx[™] expression clones should become sensitive to Zeocin[™] (see Note on page 22); therefore, your selection medium should not contain Zeocin[™]. Remember that your selection medium should contain blasticidin to select for the pcDNA6/TR plasmid.**

1. Cotransfect your mammalian Flp-In[™] T-REx[™] host cells with a 9:1 ratio of pOG44:pcDNA5/FRT/TO[®] plasmid DNA (see above) using the desired protocol. Remember to include a plate of untransfected cells as a negative control and the pcDNA5/FRT/TO/CAT[®] plasmid as a positive control.
2. 24 hours after transfection, wash the cells and add fresh medium to the cells.
3. 48 hours after transfection, split the cells into fresh medium. Split the cells such that they are no more than 25% confluent. If the cells are too dense, the antibiotic will not kill the cells. Antibiotics work best on actively dividing cells.
4. Incubate the cells at 37°C for 2-3 hours until they have attached to the culture dish.
5. Remove the medium and add fresh medium containing hygromycin (and blasticidin) at the pre-determined concentration required for your cell line.
6. Feed the cells with selective medium every 3-4 days until foci can be identified.
7. Pick 5-20 hygromycin-resistant foci and expand the cells. Verify that the pcDNA5/FRT/TO[®] construct has integrated into the FRT site by testing each clone for Zeocin[™] sensitivity and lack of β -galactosidase activity.

Note: You may also screen a polyclonal population of cells, if desired (see the next page).

8. Select those clones that are hygromycin-resistant, Zeocin[™]-sensitive, and LacZ⁻, and proceed to the next page to assay for tetracycline-regulated expression of your gene of interest.

continued on next page

Generating Flp-In[™] T-REx[™] Expression Cell Lines, continued

Polyclonal Selection

If you use a single integrant as your Flp-In[™] T-REx[™] host cell line, all of the hygromycin-resistant foci that you obtain after cotransfection of pcDNA5/FRT/TO[®] and pOG44 and selection with hygromycin should be isogenic (*i.e.* pcDNA5/FRT/TO[®] should integrate into the same genomic locus in every clone, therefore, all clones should be identical). Having isogenic clones should allow you to perform “polyclonal” selection and screening of your hygromycin-resistant cells. If you wish, you do not need to pick and screen separate foci for expression of your protein of interest. After hygromycin selection, simply pool the foci and screen the entire population of cells for tetracycline-regulated expression of your protein of interest.

Induction of Gene Expression

Guidelines are provided below to induce expression of your protein of interest with tetracycline. Expression conditions may vary depending on the nature of your protein of interest and on the cell line; therefore, some empirical experimentation may be needed to determine the optimal conditions for inducible expression.

Plate your Flp-In[™] T-REx[™] expression cell line in medium containing blasticidin and hygromycin.

To induce expression of the gene of interest, remove medium and add fresh medium containing the appropriate concentration of tetracycline to the cells. In general, we recommend that you add tetracycline to a final concentration of 1 μ g/ml (5 μ l of a 1 mg/ml stock per 5 ml of medium) to the cells and incubate the cells for 24 hours at 37°C.

Harvest the cells and assay for expression of your gene.

Optimization of Expression

You may want to vary the concentration of tetracycline (0.1 to 1 μ g/ml) and time of exposure to tetracycline (8 to 48 hours) to optimize or modulate expression for your cell line.

Other Inducers

You may use doxycycline as an alternative inducing agent in the Flp-In[™] T-REx[™] System. Doxycycline is similar to tetracycline in its mechanism of action, and exhibits similar dose response and induction characteristics as tetracycline in the Flp-In[™] T-REx[™] System. Doxycycline has been shown to have a longer half-life than tetracycline (48 hours vs. 24 hours, respectively). Doxycycline may be obtained from Sigma (Catalog no. D9891).

Appendix

Recipes

LB (Luria-Bertani) Medium and Plates

Composition:

10 g Tryptone
10 g NaCl
5 g Yeast Extract
pH 7.0

1. Combine the dry reagents above and add deionized, distilled water to 950 ml.
2. Adjust the pH of the solution to 7.0 with NaOH and bring the volume up to 1 liter.
3. Autoclave on liquid cycle for 20 minutes at 15 psi. Allow solution to cool to 55°C and add antibiotic if needed.
4. Store at room temperature or at +4°C.

LB agar plates

1. Prepare LB medium as above, but add 15 g/L agar before autoclaving.
 2. Autoclave on liquid cycle for 20 minutes at 15 psi.
 3. After autoclaving, cool to ~55°C, add antibiotic (*i.e.* 50-100 µg/ml of ampicillin), and pour into 10 cm plates.
 4. Let harden, then invert and store at +4°C, in the dark.
-

Low Salt LB Medium with Blasticidin

Low Salt LB Medium:

10 g Tryptone
5 g NaCl
5 g Yeast Extract

1. Combine the dry reagents above and add deionized, distilled water to 950 ml. Adjust pH to 7.0 with 1 N NaOH. Bring the volume up to 1 liter. For plates, add 15 g/L agar before autoclaving.
 2. Autoclave on liquid cycle at 15 psi and 121°C for 20 minutes.
 3. Allow the medium to cool to at least 55°C before adding the blasticidin to 50 g/ml final concentration.
 4. Store plates at +4°C in the dark. Plates containing blasticidin are stable for up to 2 weeks.
-

continued on next page

Recipes, continued

Phosphate-Buffered Saline (PBS)

137 mM NaCl
2.7 mM KCl
10 mM Na₂HPO₄
1.8 mM KH₂PO₄

1. Dissolve the following in 800 ml of deionized water:
8 g NaCl
0.2 g KCl
1.44 g Na₂HPO₄
0.24 g KH₂PO₄
 2. Adjust pH to 7.4 with concentrated HCl.
 3. Bring the volume to 1 liter and autoclave for 20 minutes on liquid cycle.
 4. Store at room temperature or at +4°C.
-

Zeocin™


Zeocin™

Zeocin™ is a member of the bleomycin/phleomycin family of antibiotics isolated from *Streptomyces*. Antibiotics in this family are broad spectrum antibiotics that act as strong anti-bacterial and anti-tumor drugs. They show strong toxicity against bacteria, fungi (including yeast), plants, and mammalian cells (Baron *et al.*, 1992; Drocourt *et al.*, 1990; Mulsant *et al.*, 1988; Perez *et al.*, 1989).

The Zeocin™ resistance protein has been isolated and characterized (Calmels *et al.*, 1991; Drocourt *et al.*, 1990). This protein, the product of the *Sh ble* gene (*Streptoalloteichus hindustanus* bleomycin gene), is a 13.7 kDa protein that binds Zeocin™ and inhibits its DNA strand cleavage activity. Expression of this protein in eukaryotic and prokaryotic hosts confers resistance to Zeocin™.

Molecular Weight, Formula, and Structure

The formula for Zeocin™ is $C_{60}H_{89}N_{21}O_{21}S_3$ and the molecular weight is 1,535. The diagram below shows the structure of Zeocin™.



Applications of Zeocin™

Zeocin™ is used for selection in mammalian cells (Mulsant *et al.*, 1988); plants (Perez *et al.*, 1989); yeast (Baron *et al.*, 1992); and prokaryotes (Drocourt *et al.*, 1990). Typically, Zeocin™ concentrations ranging from 50 to 1000 $\mu\text{g/ml}$ are used for selection in mammalian cells. Before transfection, we recommend that you first test the sensitivity of your mammalian host cell to Zeocin™ as natural resistance varies among cell lines.

continued on next page

Zeocin[™], continued

Handling Zeocin[™]

Store Zeocin[™] at -20°C and thaw on ice before use.

Zeocin[™] is light sensitive. Store drug, plates, and medium containing drug in the dark.

Wear gloves, a laboratory coat, and safety glasses or goggles when handling solutions containing Zeocin[™].

Zeocin[™] is toxic. Do not ingest or inhale solutions containing the drug.

Ordering Information

Zeocin[™] can be purchased from Invitrogen. For your convenience, the drug is prepared in autoclaved, deionized water and available in 1.25 ml aliquots at a concentration of 100 mg/ml. The stability of Zeocin[™] is guaranteed for six months, if stored at -20°C.

Amount	Catalog no.
1 gram	R250-01
5 grams	R250-05


Blasticidin

Blasticidin

Blasticidin S HCl is a nucleoside antibiotic isolated from *Streptomyces griseochromogenes* which inhibits protein synthesis in both prokaryotic and eukaryotic cells (Takeuchi *et al.*, 1958; Yamaguchi *et al.*, 1965). Resistance is conferred by expression of either one of two blasticidin S deaminase genes: *bsd* from *Aspergillus terreus* (Kimura *et al.*, 1994) or *bsr* from *Bacillus cereus* (Izumi *et al.*, 1991). These deaminases convert blasticidin S to a non-toxic deaminohydroxy derivative (Izumi *et al.*, 1991).

Molecular Weight, Formula, and Structure

The formula for blasticidin S is $C_{17}H_{26}N_8O_5 \cdot HCl$, and the molecular weight is 458.9. The diagram below shows the structure of blasticidin.



Handling Blasticidin

Always wear gloves, mask, goggles, and protective clothing (*e.g.* a laboratory coat) when handling blasticidin. Weigh out blasticidin and prepare solutions in a hood.

Preparing and Storing Stock Solutions


Blasticidin may be obtained separately from Invitrogen (Catalog no. R210-01) in 50 mg aliquots. Blasticidin is soluble in water. Sterile water is generally used to prepare stock solutions of 5 to 10 mg/ml.

- Dissolve blasticidin in sterile water and filter-sterilize the solution.
- Aliquot in small volumes suitable for one time use (see next to last point below) and freeze at -20°C for long-term storage or store at +4°C for short-term storage.
- Aqueous stock solutions are stable for 1-2 weeks at +4°C and 6-8 weeks at -20°C.
- pH of the aqueous solution should be 7.5 to prevent inactivation of blasticidin.
- Do not subject stock solutions to freeze/thaw cycles (**do not store in a frost-free freezer**).
- Upon thawing, use what you need and store the thawed stock solution at +4°C for up to 2 weeks.
- Medium containing blasticidin may be stored at +4°C for up to 2 weeks.

pFRT/*lacZeo* Vector

Map of pFRT/*lacZeo*

pFRT/*lacZeo* is a 8106 bp vector that expresses a fusion protein containing β -galactosidase and the Zeocin[™] resistance marker under the control of SV40 early promoter. Note that neither the *lacZ* gene nor the Zeocin[™] resistance gene contains its native ATG initiation codon. The ATG initiation codon is placed directly upstream of a FRT site and allows expression of the *lacZ*-Zeocin[™] fusion gene in cells. The figure below summarizes the features of the pFRT/*lacZeo*. **The complete sequence for pFRT/*lacZeo* is available for downloading from our World Wide Web site (www.invitrogen.com) or by contacting Technical Service (see page 38).**



Comments for pFRT/*lacZeo* 8106 nucleotides

SV40 early promoter and origin: bases 278-604

ATG initiation codon: bases 609-611

FRT site: bases 614-661

LacZ-Zeocin[™] fusion gene

LacZ ORF (no ATG): bases 675-3722

Zeocin[™] resistance gene (no ATG): bases 3810-4181

SV40 early polyadenylation signal: bases 5102-5425

bla promoter: bases 6201-6299

Ampicillin (*bla*) resistance gene: bases 6300-7160

pUC origin: bases 7305-7978

continued on next page

pFRT//lacZeo Vector, continued

Features of pFRT//lacZeo


The table below describes the relevant features of pFRT//lacZeo. All features have been functionally tested.

Feature	Benefit
SV40 early promoter and origin	Permits efficient, high-level expression of the <i>lacZ-Zeocin</i> [™] fusion gene in mammalian cells and episomal replication in cells expressing the SV40 large T antigen
ATG initiation codon	Allows translation initiation of the LacZ-Zeocin [™] fusion protein
Flp Recombination Target (FRT) site	Encodes a 34 bp (+14 bp non-essential) sequence that serves as the binding and cleavage site for Flp recombinase (Gronostajski and Sadowski, 1985; Jayaram, 1985; Senecoff <i>et al.</i> , 1985)
<i>lacZ-Zeocin</i> [™] fusion gene	Encodes a fusion protein containing β -galactosidase and the Zeocin [™] resistance marker to permit selection of stable mammalian cell lines with Zeocin [™] and screening by β -galactosidase activity assay
SV40 early polyadenylation signal	Allows efficient transcription termination and polyadenylation of mRNA
<i>bla</i> promoter	Allows expression of the ampicillin (<i>bla</i>) resistance gene
Ampicillin (<i>bla</i>) resistance gene (β -lactamase)	Allows selection of transformants in <i>E. coli</i>
pUC origin	Permits high-copy number replication and growth in <i>E. coli</i>

pcDNA6/TR[®]

Map of pcDNA6/TR[®]

pcDNA6/TR[®] is a 6662 bp vector that expresses the Tet repressor under the control of the human CMV promoter. The figure below summarizes the features of the pcDNA6/TR[®] vector. **The complete sequence for pcDNA6/TR[®] is available for downloading from our World Wide Web site (www.invitrogen.com) or by contacting Technical Service (see page 38).**



Comments for pcDNA6/TR[®] 6662 nucleotides

CMV promoter: bases 232-819

Rabbit β -globin intron II (IVS): bases 1028-1600

TetR gene: bases 1684-2304

SV40 early polyadenylation sequence: bases 2346-2477

f1 origin: bases 2897-3325

SV40 promoter and origin: bases 3335-3675

EM-7 promoter: bases 3715-3781

Blasticidin resistance gene: bases 3782-4180

SV40 early polyadenylation sequence: bases 4338-4468

pUC origin: bases 4851-5521

bla promoter: bases 6521-6625 (complementary strand)

Ampicillin (*bla*) resistance gene: bases 5666-6526 (complementary strand)

TetR Gene

The *TetR* gene used in pcDNA6/TR[®] was originally isolated from the Tn10 transposon which confers resistance to tetracycline in *E. coli* and other enteric bacteria (Postle *et al.*, 1984). The *TetR* gene from Tn10 encodes a class B Tet repressor and is often referred to as *TetR(B)* in the literature (Hillen and Berens, 1994).

The *TetR* gene encodes a repressor protein of 207 amino acids with a calculated molecular weight of 23 kDa. For more information about the Tet repressor and its interaction with the Tet operator, refer to the review by Hillen and Berens (1994).

continued on next page

pcDNA6/TR[®] Vector, continued

Features of pcDNA6/TR[®]


The table below describes the relevant features of pcDNA6/TR[®]. The vector includes the rabbit β -globin intron II to enhance expression of the *TetR* gene. For a more detailed description of the *TetR* gene and the Tet repressor, refer to the previous page. All features have been functionally tested.

Feature	Benefit
Human cytomegalovirus (CMV) immediate early promoter	Permits high-level expression of the <i>TetR</i> gene (Andersson <i>et al.</i> , 1989; Boshart <i>et al.</i> , 1985; Nelson <i>et al.</i> , 1987)
Rabbit β -globin intron II (IVS)	Enhances expression of the <i>TetR</i> gene (van Ooyen <i>et al.</i> , 1979) in cultured cells
<i>TetR</i> gene	Encodes the Tet repressor that binds to <i>tet</i> operator sequences to repress transcription of the gene of interest in the absence of tetracycline (Postle <i>et al.</i> , 1984; Yao <i>et al.</i> , 1998)
SV40 early polyadenylation signal	Permits efficient transcription termination and polyadenylation of mRNA
f1 origin	Allows rescue of single-stranded DNA
SV40 early promoter and origin	Allows efficient, high-level expression of the blasticidin resistance gene in mammalian cells and episomal replication in cells expressing SV40 large T antigen
EM-7 promoter	Synthetic prokaryotic promoter for expression of the blasticidin resistance gene in <i>E. coli</i>
Blasticidin (<i>bsd</i>) resistance gene	Allows selection of stable transfectants in mammalian cells (Kimura <i>et al.</i> , 1994)
SV40 early polyadenylation signal	Allows efficient transcription termination and polyadenylation of mRNA
pUC origin	Permits high-copy number replication and growth in <i>E. coli</i>
<i>bla</i> promoter	Allows expression of the ampicillin (<i>bla</i>) resistance gene
Ampicillin (<i>bla</i>) resistance gene (β -lactamase)	Allows selection of transformants in <i>E. coli</i>

pOG44 Vector

Map of pOG44

pOG44 is a 5785 bp vector that expresses the Flp recombinase under the control of the human CMV promoter as previously described (O'Gorman *et al.*, 1991). The vector contains a synthetic intron to enhance expression of the *FLP* gene. Note that the vector does not contain an antibiotic resistance marker to allow stable selection in mammalian cells. The figure below summarizes the features of the pOG44 vector. **The complete sequence for pOG44 is available for downloading from our World Wide Web site (www.invitrogen.com) or by contacting Technical Service (see page 38).**



Comments for pOG44 5785 nucleotides

CMV promoter: bases 234-821

Synthetic intron: bases 871-1175

FLP ORF: bases 1202-2473

SV40 late polyadenylation signal: bases 2597-2732

pUC origin: bases 3327-3993 (complementary strand)

bla promoter: bases 4999-5097 (complementary strand)

Ampicillin (*bla*) resistance gene: bases 4138-4998 (complementary strand)

FLP Gene

The *FLP* gene was originally isolated from the *Saccharomyces cerevisiae* 2 plasmid (Broach *et al.*, 1982; Broach and Hicks, 1980), and encodes a site-specific recombinase that is a member of the integrase family of recombinases (Argos *et al.*, 1986). The Flp recombinase mediates a site-specific recombination reaction between interacting DNA molecules via the pairing of interacting FRT sites. For more information about site-specific recombination, refer to page 5 and published reviews (Craig, 1988; Sauer, 1994).

The native *FLP* gene encodes a protein of 423 amino acids with a calculated molecular weight of 49 kDa. The *FLP* gene expressed from pOG44 encodes a temperature-sensitive Flp recombinase which carries a point mutation (flp-F70L) that results in a change in amino acid 70 from phenylalanine to leucine (Buchholz *et al.*, 1996). For more information about the properties of the flp-F70L protein, refer to page 22 and Buchholz *et al.*, 1996.

continued on next page

pOG44 Vector, continued

Features of pOG44 The table below describes the relevant features of pOG44. All features have been functionally tested.

Feature	Benefit
Human cytomegalovirus (CMV) immediate early promoter	Permits high-level expression of the <i>FLP</i> gene (Andersson <i>et al.</i> , 1989; Boshart <i>et al.</i> , 1985; Nelson <i>et al.</i> , 1987)
Synthetic intron	Hybrid fragment which contains sequences derived from the adenovirus major late region and an IgG variable region (Huang and Gorman, 1990; O'Gorman <i>et al.</i> , 1991) and functions to enhance expression of the <i>FLP</i> gene
<i>FLP</i> ORF	Encodes a temperature-sensitive Flp recombinase (Buchholz <i>et al.</i> , 1996) that mediates conservative recombination via FRT sites (O'Gorman <i>et al.</i> , 1991)
SV40 late polyadenylation signal	Permits efficient transcription termination and polyadenylation of mRNA
pUC origin	Permits high-copy number replication and growth in <i>E. coli</i>
<i>bla</i> promoter	Allows expression of the ampicillin (<i>bla</i>) resistance gene
Ampicillin (<i>bla</i>) resistance gene (β -lactamase)	Allows selection of transformants in <i>E. coli</i>

Technical Service

World Wide Web



Visit the Invitrogen Web Resource using your World Wide Web browser. At the site, you can:

Get the scoop on our hot new products and special product offers

View and download vector maps and sequences

Download manuals in Adobe® Acrobat® (PDF) format

Explore our catalog with full color graphics

Obtain citations for Invitrogen products

Request catalog and product literature

Once connected to the Internet, launch your Web browser (Internet Explorer 5.0 or newer or Netscape 4.0 or newer), then enter the following location (or URL):

<http://www.invitrogen.com>

...and the program will connect directly. Click on underlined text or outlined graphics to explore. Don't forget to put a bookmark at our site for easy reference!

Contact Us

For more information or technical assistance, please call, write, fax, or email. Additional international offices are listed on our Web page (www.invitrogen.com).

United States Headquarters:

Invitrogen Corporation
1600 Faraday Avenue
Carlsbad, CA 92008 USA
Tel: 1 760 603 7200
Tel (Toll Free): 1 800 955 6288
Fax: 1 760 602 6500
E-mail:
tech_service@invitrogen.com

Japanese Headquarters

Invitrogen Japan K.K.
Nihonbashi Hama-Cho Park Bldg. 4F
2-35-4, Hama-Cho, Nihonbashi
Tel: 81 3 3663 7972
Fax: 81 3 3663 8242
E-mail: jpinfo@invitrogen.com

European Headquarters:

Invitrogen Ltd
3 Fountain Drive
Inchinnan Business Park
Paisley PA4 9RF, UK
Tel (Free Phone Orders): 0800 269 210
Tel (General Enquiries): 0800 5345 5345
Fax: +44 (0) 141 814 6287
E-mail: eurotech@invitrogen.com

MSDS Requests

To request an MSDS, please visit our Web site (www.invitrogen.com) and follow the instructions below.

1. On the home page, go to the left-hand column under 'Technical Resources' and select 'MSDS Requests'.
2. Follow instructions on the page and fill out all the required fields.
3. To request additional MSDSs, click the 'Add Another' button.
4. All requests will be faxed unless another method is selected.
5. When you are finished entering information, click the 'Submit' button. Your MSDS will be sent within 24 hours.

continued on next page

Technical Service, continued

Emergency Information

In the event of an emergency, customers of Invitrogen can call the 3E Company, 24 hours a day, 7 days a week for disposal or spill information. The 3E Company can also connect the customer with poison control or with the University of California at San Diego Medical Center doctors.

3E Company
Voice: 1-760-602-8700

Limited Warranty

Invitrogen is committed to providing our customers with high-quality goods and services. Our goal is to ensure that every customer is 100% satisfied with our products and our service. If you should have any questions or concerns about an Invitrogen product or service, please contact our Technical Service Representatives.

Invitrogen warrants that all of its products will perform according to the specifications stated on the certificate of analysis. The company will replace, free of charge, any product that does not meet those specifications. This warranty limits Invitrogen Corporation's liability only to the cost of the product. No warranty is granted for products beyond their listed expiration date. No warranty is applicable unless all product components are stored in accordance with instructions. Invitrogen reserves the right to select the method(s) used to analyze a product unless Invitrogen agrees to a specified method in writing prior to acceptance of the order.

Invitrogen makes every effort to ensure the accuracy of its publications, but realizes that the occasional typographical or other error is inevitable. Therefore Invitrogen makes no warranty of any kind regarding the contents of any publications or documentation. If you discover an error in any of our publications, please report it to our Technical Service Representatives.

Invitrogen assumes no responsibility or liability for any special, incidental, indirect or consequential loss or damage whatsoever. The above limited warranty is sole and exclusive. No other warranty is made, whether expressed or implied, including any warranty of merchantability or fitness for a particular purpose.

Purchaser Notification

Introduction

Use of the Flp-In[™] T-REx[™] System and its components (“System”) is covered under a number of different licenses including those detailed below.

The Nature of the Invitrogen License

Invitrogen Corporation (“Invitrogen”) has a license to sell the System to scientists **for academic research purposes only**, under the terms described below. Use of the System for any Commercial Purpose (as defined below) requires the user to obtain commercial licenses as detailed below. Note that each such license would cover only one part of the System. Before using the System, please read the terms and conditions set forth below. Your use of the System shall constitute acknowledgment and acceptance of these terms and conditions. If you do not wish to use the System pursuant to these terms and conditions, please contact Invitrogen’s Technical Services within 10 days to return the unused and unopened System for a full credit. Otherwise, please complete the Product User Registration Card and return it to Invitrogen.

Terms and Conditions

Invitrogen grants you a non-exclusive license to use the enclosed System for academic research or for commercial evaluation purposes only. The System is being transferred to you in furtherance of, and reliance on, such license. You may not use the System, or the materials contained therein, for any Commercial Purpose without licenses for such purpose.

One Year Evaluation

If you are a commercial entity, your right to use the System expires after one year. Any commercial entity that wishes to use the System beyond this one-year period must obtain a commercial license from Invitrogen. Note that such a license would cover only one part of the System. Additional licenses for commercial use, as described on pages 41-43, may be required. Commercial entities will be contacted by Invitrogen during this one-year period regarding their desire to obtain a commercial license.

You may terminate your use of the System at any time by destroying all System components in your control. Your right to use the System will also terminate automatically if you fail to comply with the terms and conditions set forth therein. You shall, upon such termination of your rights, destroy all System components in your control, and notify Invitrogen of such in writing.

Definition of Commercial Purpose

Commercial Purpose includes:

- any use of the System or Expression Products in a Commercial Product;
- any use of the System or Expression Products in the manufacture of a Commercial Product;
- any sale of the System or Expression Products;
- any use of the System or Expression Products to facilitate or advance research or development of a Commercial Product; and
- any use of the System or Expression Products to facilitate or advance any research or development program the results of which will be applied to the development of a Commercial Product.

“Expression Products” means products expressed with the System, or with the use of any vectors or host strains in the System. “Commercial Product” means any product intended for sale or commercial use.

continued on next page

Purchaser Notification, continued

Individual Responsibilities

Access to the System must be limited solely to those officers, employees and students of your entity who need access to perform the aforementioned research. Each such officer, employee and student must be informed of these terms and conditions and agree, in writing, to be bound by same. You may not distribute the System or the vectors or host strains contained in it to others. You may not transfer modified, altered, or original material from the System to a third party without written notification to, and written approval from Invitrogen. You may not assign, sub-license, rent, lease or otherwise transfer any of the rights or obligations set forth herein, except as expressly permitted by Invitrogen.

Governing Law

This license shall be governed in its interpretation and enforcement by the laws of the United States and California.

FLP-Mediated Gene Modification

This product is licensed under U.S. Patent Nos. 5,654,182 and 5,677,177 and is **for research purposes only**. Inquiries about licensing for commercial or other uses should be directed to:

The Salk Institute for Biological Studies
10010 North Torrey Pines Road
La Jolla, CA 92037
Attn.: Department of Intellectual Property and Technology Transfer
Phone: 858-453-4100 ext 1275
Fax: 858-450-0509
Email: amueller@salk.edu

T-REx[™] System License

This product is licensed under patents pending in the U.S. and other countries and is **for research purposes only**. Inquiries about licensing for commercial or other uses should be directed to:

Licensing Coordinator
Invitrogen Corporation
1600 Faraday Avenue
Carlsbad, CA 92008
Phone: 760-603-7200
Fax: 760-703-7229

CMV Promoter

Use of the CMV promoter is covered under U.S. Patent Nos. 5,168,062 and 5,385,839 owned and licensed by the University of Iowa Research Foundation and may be used **for research purposes only**. Commercial users must obtain a license to these patents directly from the University of Iowa Research Foundation. Inquiries for commercial use should be directed to:

Brenda Akins
University of Iowa Research Foundation (UIRF)
214 Technology Innovation Center
Iowa City, IA 52242
Phone: 319-335-4549

continued on next page

Purchaser Notification, continued

Use of Prokaryotic Control Elements in Eukaryotes

This product is also licensed under U.S. Patent No. 4,833,080 and corresponding patents in other countries. It may not be used for gene expression in plants nor certain molecular modifications and screening. Inquiries about licensing for commercial manufacture or use outside the research kits and reagents market should be directed to:

Office of Technology and Trademark Licensing
Harvard University
University Place, Suite 410 South
124 Mt. Auburn Street
Cambridge, MA 02138
Phone: 617-495-3067
Fax: 617-495-9568

Inquiries regarding commercial use in the research market should be directed to:

Licensing Coordinator
Invitrogen Corporation
1600 Faraday Avenue
Carlsbad, CA 92008
Phone: 760-603-7200
Fax: 760-603-7229

BGH PolyA Sequence License

The bovine growth hormone (BGH) polyadenylation sequence is licensed under U.S. Patent No. 5,122,458 for research purposes only. "Research purposes" means uses directed to the identification of useful recombinant proteins and the investigation of the recombinant expression of proteins, which uses shall in no event include any of the following:

- a. any use in humans of a CLAIMED DNA or CLAIMED CELL;
- b. any use in human of protein or other substance expressed or made at any stage of its production with the use of a CLAIMED DNA or a CLAIMED CELL;
- c. any use in which a CLAIMED DNA or CLAIMED CELL would be sold or transferred to another party other than Invitrogen, its AFFILIATE, or its SUBLICENSEE;
- d. any use in connection with the expression or production of a product intended for sale or commercial use; or
- e. any use for drug screening or drug development.

Inquiries for commercial use should be directed to:

Bennett Cohen, Ph.D.
Research Corporation Technologies
101 North Wilmot Road, Suite 600
Tucson, AZ 85711-3335
Tel: 520-748-4443
Fax: 520-748-0025

continued on next page

Purchaser Notification, continued

Zeocin™

Zeocin™ is a trademark of CAYLA, Toulouse, France. For commercial license information, please contact:

Licensing Coordinator
Invitrogen Corporation
1600 Faraday Avenue
Carlsbad, CA 92008
Phone: 760-603-7200
Fax: 760-602-6500

Blasticidin Use

Blasticidin and the blasticidin resistance gene are licensed from Kaken Pharmaceutical and the Institute of Physical and Chemical Research, Japan and may be used **for research purposes only**. Inquiries for commercial use should be directed to:

Kaken Pharmaceutical Company, Ltd.
Bunkyo Green Court, Center Office Building, 19-20 Fl.
28-8 Honkomagome 2-chome
Bunkyo-ku, Tokyo 113-8650
Japan
Phone: +81 3-5977-5008
Fax: +81 3-5977-5008

Product User Registration Card

Please complete and return the enclosed Product User Registration Card for each Flp-In™ T-REx™ Core Kit that you purchase. This will serve as a record of your purchase and registration will allow Invitrogen to provide you with critical product updates. The agreement outlined above becomes effective upon our receipt of your Product User Registration Card or 10 days following the sale of the Flp-In™ T-REx™ Core Kit to you. Use of the System at any time results in immediate obligation to the terms and conditions stated in this license agreement.

Product Qualification

Introduction

This section describes the criteria used to qualify the components of the Flp-In™ T-REx™ Core Kit.

Vectors

Each vector is qualified by restriction enzyme digestion with specific restriction enzymes as listed below. Restriction digests must demonstrate the correct banding pattern when electrophoresed on an agarose gel (see below). For a list of the restriction enzymes used to qualify the pcDNA5/FRT/TO® and pcDNA5/FRT/TO/CAT® vectors, refer to the pcDNA5/FRT/TO® manual.

Vector	Restriction Enzymes	Expected Results (bp)
pFRT/ <i>lacZeo</i>	<i>Kpn</i> I	No site
	<i>Xba</i> I	8106
pcDNA6/TR®	<i>Pme</i> I	1701, 4961
	<i>Sal</i> I	2185, 4477
pOG44	<i>Kpn</i> I	5438, 347
	<i>Xba</i> I	5785

Primers

Sequencing primers are lot-qualified by DNA sequencing experiments using the dideoxy chain termination technique.

Tetracycline

The pBR322 plasmid is transformed into TOP10 *E. coli* cells. Greater than 95% of transformants must be viable when plated on Low Salt LB Agar with and without 15 g/ml tetracycline.

References

- Andersson, S., Davis, D. L., Dahlbäck, H., Jörnvall, H., and Russell, D. W. (1989). Cloning, Structure, and Expression of the Mitochondrial Cytochrome P-450 Sterol 26-Hydroxylase, a Bile Acid Biosynthetic Enzyme. *J. Biol. Chem.* *264*, 8222-8229.
- Andrews, B. J., Proteau, G. A., Beatty, L. G., and Sadowski, P. D. (1985). The FLP Recombinase of the 2 Micron Circle DNA of Yeast: Interaction with its Target Sequences. *Cell* *40*, 795-803.
- Argos, P., Landy, A., Abremski, K., Egan, J. B., Ljungquist, E. H., Hoess, R. H., Kahn, M. L., Kalionis, B., Narayana, S. V. L., and Pierson, L. S. (1986). The Integrase Family of Site-Specific Recombinases: Regional Similarities and Global Diversity. *EMBO J.* *5*, 433-440.
- Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1994). *Current Protocols in Molecular Biology* (New York: Greene Publishing Associates and Wiley-Interscience).
- Baron, M., Reynes, J. P., Stassi, D., and Tiraby, G. (1992). A Selectable Bifunctional β -Galactosidase: Phleomycin-resistance Fusion Protein as a Potential Marker for Eukaryotic Cells. *Gene* *114*, 239-243.
- Boshart, M., Weber, F., Jahn, G., Dorsch-Häsler, K., Fleckenstein, B., and Schaffner, W. (1985). A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus. *Cell* *41*, 521-530.
- Broach, J. R., Guarascio, V. R., and Jayaram, M. (1982). Recombination Within the Yeast Plasmid 2mu Circle is Site-specific. *Cell* *29*, 227-234.
- Broach, J. R., and Hicks, J. B. (1980). Replication and Recombination Functions Associated with the Yeast Plasmid, 2 mu Circle. *Cell* *21*, 501-508.
- Buchholz, F., Ringrose, L., Angrand, P. O., Rossi, F., and Stewart, A. F. (1996). Different Thermostabilities of FLP and Cre Recombinases: Implications for Applied Site-specific Recombination. *Nuc. Acids Res.* *24*, 4256-4262.
- Calmels, T., Parriche, M., Burand, H., and Tiraby, G. (1991). High Efficiency Transformation of *Tolypocladium geodes* Conidiospores to Phleomycin Resistance. *Curr. Genet.* *20*, 309-314.
- Chen, C., and Okayama, H. (1987). High-Efficiency Transformation of Mammalian Cells by Plasmid DNA. *Molec. Cell. Biol.* *7*, 2745-2752.
- Chu, G., Hayakawa, H., and Berg, P. (1987). Electroporation for the Efficient Transfection of Mammalian Cells with DNA. *Nucleic Acids Res.* *15*, 1311-1326.
- Craig, N. L. (1988). The Mechanism of Conservative Site-Specific Recombination. *Ann. Rev. Genet.* *22*, 77-105.
- Drocourt, D., Calmels, T. P. G., Reynes, J. P., Baron, M., and Tiraby, G. (1990). Cassettes of the *Streptoalloteichus hindustanus ble* Gene for Transformation of Lower and Higher Eukaryotes to Phleomycin Resistance. *Nucleic Acids Res.* *18*, 4009.
- Felgner, P. L., Holm, M., and Chan, H. (1989). Cationic Liposome Mediated Transfection. *Proc. West. Pharmacol. Soc.* *32*, 115-121.
- Felgner, P. L. a., and Ringold, G. M. (1989). Cationic Liposome-Mediated Transfection. *Nature* *337*, 387-388.
- Gritz, L., and Davies, J. (1983). Plasmid-Encoded Hygromycin-B Resistance: The Sequence of Hygromycin-B-Phosphotransferase Gene and its Expression in *E. coli* and *S. Cerevisiae*. *Gene* *25*, 179-188.

continued on next page

References, continued

- Gronostajski, R. M., and Sadowski, P. D. (1985). Determination of DNA Sequences Essential for FLP-mediated Recombination by a Novel Method. *J. Biol. Chem.* 260, 12320-12327.
- Hillen, W., and Berens, C. (1994). Mechanisms Underlying Expression of Tn10 Encoded Tetracycline Resistance. *Annu. Rev. Microbiol.* 48, 345-369.
- Hillen, W., Gatz, C., Altschmied, L., Schollmeier, K., and Meier, I. (1983). Control of Expression of the Tn10-encoded Tetracycline Resistance Genes: Equilibrium and Kinetic Investigations of the Regulatory Reactions. *J. Mol. Biol.* 169, 707-721.
- Huang, M. T. F., and Gorman, C. M. (1990). Intervening Sequences Increase Efficiency of RNA 3' Processing and Accumulation of Cytoplasmic RNA. *Nuc. Acids Res.* 18, 937-947.
- Jayaram, M. (1985). Two-micrometer Circle Site-specific Recombination: The Minimal Substrate and the Possible Role of Flanking Sequences. *Proc. Natl. Acad. Sci. USA* 82, 5875-5879.
- Miller, J. H. (1972). *Experiments in Molecular Genetics* (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory).
- Mulsant, P., Tiraby, G., Kallerhoff, J., and Perret, J. (1988). Phleomycin Resistance as a Dominant Selectable Marker in CHO Cells. *Somat. Cell Mol. Genet.* 14, 243-252.
- Nelson, J. A., Reynolds-Kohler, C., and Smith, B. A. (1987). Negative and Positive Regulation by a Short Segment in the 5'-Flanking Region of the Human Cytomegalovirus Major Immediate-Early Gene. *Molec. Cell. Biol.* 7, 4125-4129.
- Neumann, J. R., Morency, C. A., and Russian, K. O. (1987). A Novel Rapid Assay for Chloramphenicol Acetyltransferase Gene Expression. *BioTechniques* 5, 444-447.
- O'Gorman, S., Fox, D. T., and Wahl, G. M. (1991). Recombinase-Mediated Gene Activation and Site-Specific Integration in Mammalian Cells. *Science* 251, 1351-1355.
- Palmer, T. D., Hock, R. A., Osborne, W. R. A., and Miller, A. D. (1987). Efficient Retrovirus-Mediated Transfer and Expression of a Human Adenosine Deaminase Gene in Diploid Skin Fibroblasts from an Adenosine-Deficient Human. *Proc. Natl. Acad. Sci. U.S.A.* 84, 1055-1059.
- Perez, P., Tiraby, G., Kallerhoff, J., and Perret, J. (1989). Phleomycin Resistance as a Dominant Selectable Marker for Plant Cell Transformation. *Plant Mol. Biol.* 13, 365-373.
- Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). *Molecular Cloning: A Laboratory Manual*, Second Edition (Plainview, New York: Cold Spring Harbor Laboratory Press).
- Sauer, B. (1994). Site-Specific Recombination: Developments and Applications. *Curr. Opin. Biotechnol.* 5, 521-527.
- Senecoff, J. F., Bruckner, R. C., and Cox, M. M. (1985). The FLP Recombinase of the Yeast 2-micron Plasmid: Characterization of its Recombination Site. *Proc. Natl. Acad. Sci. USA* 82, 7270-7274.
- Shigekawa, K., and Dower, W. J. (1988). Electroporation of Eukaryotes and Prokaryotes: A General Approach to the Introduction of Macromolecules into Cells. *BioTechniques* 6, 742-751.

continued on next page

References, continued

Wigler, M., Silverstein, S., Lee, L.-S., Pellicer, A., Cheng, Y.-C., and Axel, R. (1977). Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells. *Cell* 11, 223-232.

Yao, F., Svensjö, T., Winkler, T., Lu, M., Eriksson, C., and Eriksson, E. (1998). Tetracycline Repressor, tetR, Rather than the tetR-Mammalian Cell Transcription Factor Fusion Derivatives, Regulates Inducible Gene Expression in Mammalian Cells. *Hum. Gene Ther.* 9, 1939-1950.

©2000-2001 Invitrogen Corporation. All rights reserved.